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ABSTRACT 
The allogenic bone marrow derived mesenchymal 
stem cells transplantation was given to the newborn 
girl diagnosed with osteogenesis imperfecta type III, 
with multiple bone fractures, extreme shortness and 
limbs deformities. The treatment was performed at 
the age of 4 and 6 weeks. The clinical diagnosis was 
supported by biochemical analysis of collagen type I 
recovered from culture medium of cultivated pa- 
tient’s skin fibroblast, which revealed its triple helix 
instability at temperature about 2˚C lower than nor- 
mal. Sequencing of both genes encoding procollagen 
type I revealed heterozygous substitution G23569A in 
COL1A2 gene causing change of glycine at position 
517 to aspartate. The donor of mesenchymal stem 
cells was the girl’s father. She received two intrave- 
nous infusions of suspended cultured mesenchymal 
cells in 16 days apart without any side effects. An 
analysis of procollagen type I secreted to the culture 
medium by bone marrow-derived mesenchymal stem 
cells obtained from the patient, 3 months following 
transplantation revealed its normal triple helix stabil- 
ity. During the subsequent two years of follow up two 
new bone fractures were noted. Currently a two- 
year-old girl’s presents extreme growth and weight 
deficiency. The motoric development is also retarded, 
but the patient constantly improves and makes pro- 
gresses. 
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1. INTRODUCTION 
Osteogenesis imperfecta (OI) is a genetic disease deter-
mined by autosomal dominant negative mutation of type 
I collagen, which is commonly know as “brittle bone 
disease”. The overall birth prevalence of OI is estimated 
to range between 1 in 20,000 and 1 in 30,000. Clinically 
OI is heterogenous disorder with wide range of mani- 
festations, from very mild, through moderate, to fatally 
severe, including lethal cases [1]. It is a systemic dis- 
order affecting primarily bones but also teeth and eyes as 
well as leading to progressive hearing impairment [2]. 
Bones in this condition are fragile such that affected in-
dividuals sustain fractures after very mild trauma and 
frequent fractures, from several to tenths are observed 
throughout the patients live [3]. Multiple skeletal fea-
tures and poor healing is responsible for short stature, 
relative macrocephaly, scoliosis and bowing of the long 
bones. Two types of the OI are represented by most 
severe clinical outcome [4]. The type II OI, which is the 
most severe form of osteogenesis imperfecta and is al- 
most uniformly lethal. This form of the disorder is char- 
acterised by extreme bone fragility, leading to fetal de- 
mise or death in perinatal period [5,6]. Second one in 
severity of clinical symptoms is type III of OI, which is 
leading to serious skeletal deformities and makes the 
patient to be wheelchaired or bed ridden. The frequency 
of type II and III osteogenesis imperfecta is estimated to 
be 1 in 10000. 
The gold standard for postnatal diagnosis of OI is 
based on clinical and radiological features, confirmed 
subsequently by molecular diagnosis of collagen triple 
helix stability and detection of mutation [7]. In the 
majority of cases the cause of the OI is the mutation in 
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one of the two genes encoding procollagen type I 
polypeptide chains, namely COL1A1 and COL1A2. In 
recent years, however, new evidence surfaced shading 
light on other genes, which when mutated might lead to 
autosomal recessive forms of OI although both pro- 
collagen genes do not show the mutation [8-11]. The 
incorrect genes both encoding procollagen type I and 
potential disturbances in its posttranslational processing 
are the major causes of poor quality of extracellular 
matrix, regardless lower collagen content or its poor 
stability.  
Conventional management for patients with OI con- 
sisted of supplementation with vitamin D and minerals, 
or administration of bisphosphonates [8,12-15]. However, 
these methods did not ameliorate the symptoms of OI 
[12]. Moreover, in young teenage patients the bispho- 
sphonates cannot be used continuously, because they 
slow down bone turnover and as consequence child’s 
growth and healing of eventual bone fractures [16]. 
Another option of supportive treatment of OI patients is 
surgical and orthopedic intervention or protection with 
the use of braces, steel rods and other orthopedic equip- 
ment [reviewed in 11]. Either, supportive treatment of OI 
did not provide sufficient clinical improvement, es- 
pecially in the most severe forms. Neither the medi- 
cations or the surgical treatment can lead to permanent 
amelioration of the OI symptoms. The obvious reason is 
the genetic nature of this disorder. 
For patients with OI type II and III a cell or gene 
therapy could be offered as the only chance of life saving 
and prevention of severe disability. Already more than 
10 years ago first clinical trials were conducted for 
treating the severe type of OI with cell therapy [17]. The 
trials were then further expanded on larger group of OI 
patients [18-20].  
Here, we report a case of a girl with OI type III treated 
at the age of 4 and 6 weeks by transplantation of alloge- 
neic bone marrow derived mesenchymal stem cells 
(MSC). The diagnosis of OI was established on the base 
of clinical and radiological features, and confirmed 
subsequently by molecular diagnosis which revealed 
procollagen thermal instability and detected a missense 
mutation in COL1A2 gene.  
2. MATERIAL AND METHODS  
2.1. Patient 
A girl patient was born to a G2, P1 healthy mother at 
39/40 weeks of gestation. A child was delivered by 
caesarean section, because of abnormal fetal heart rate 
pattern, pelvic position, and severe deformities of upper 
and lower extremities detected prior to the child’s birth 
during regular monitoring of pregnancy by ultrasound 
examinations. Both parents are healthy and unrelated 
individuals. The first pregnancy of this couple was a 
miscarriage. The analysis of family pedigree did not 
show any cases of OI or any other genetic diseases. The 
birth parameters of the patient were as follow: birth 
weight 2490 g, length 44 cm, head circumference 34 cm, 
Apgar score 3, 4, 5, 7 points. In delivery room the child 
was successfully resuscitated. The patient required 
support of ventilation (nasal CPAP) shortly after birth 
and during the first three days of life. Neither mechanical 
ventilation nor oxygen therapy were needed later on.  
At the age of three days, the child was admitted to the 
Neonatal Intensive Care Unit of the Department of 
Pediatrics, Chair of Pediatrics, Jagiellonian University 
and hospitalized for subsequent three months. Clinical 
evaluation of the patient on admission revealed short 
stature, severe lower limb deformities, relative macro- 
cephaly, triangular face and blue sclera. X-ray exami- 
nation (baby-gram) showed 27 bone fractures, multiple 
deformities and reduced ossification of the skull cal- 
varion. Based on the clinical and radiological findings of 
multiple bone fractures and severe limb deformities, the 
preliminary diagnosis of type II OI was made according 
to the classification by Sillence [21]. The anthropometric 
measurements were conducted and the dermatoglyphic 
patterns were analyzed. Genomic DNA was isolated 
from cultured fibroblasts for the molecular analysis of 
the COL1A1 and COL1A2 genes. The skin biopsy was 
performed to assess the stability of produced by fibro- 
blasts collagen triple helix. The levels of serum bone 
turn-over markers (osteocalcin (OC), procollagen type I 
N-propeptide (P1NP), collagen type I crosslinked C- 
telopeptide (Ctx)) were assessed. Then, on the basis of 
the natural cause of the disease, the result of molecular 
analysis revealing heterozygous mutation in exon 26 of 
COL1A2 gene and the diminished thermal stability 
procollagen triple helix, the diagnosis was changed to 
type III osteogenesis imperfecta. The patient was 
qualified to a clinical trial entitled “Cell therapy in treat- 
ment of the patients with type II and type III osteogene- 
sis imperfecta”. The entry criteria for the study were as 
follow: 1) diagnosis of type II or III osteogenesis 
imperfecta, 2) parents agreement for participation in the 
clinical study, 3) approval of the Bioethics Committee of 
the Jagiellonian University (KBET/108/B/2007).  
2.2. Patient’s Samples 
The anthropometric measurements were conducted and 
the dermatoglyphic patterns were analyzed before 
mesenchymal cells transplantation was performed. A 
blood samples were taken to assess the level of serum 
bone markers (OC, P1NP, and Ctx). The skin biopsy was 
performed to assess the stability of collagen triple helix 
and genomic DNA purification for molecular analyses of 
COL1A1 and COL1A2 genes.  
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2.3. Survey of Collagen Genes for Mismatches  
DNA fragments of the collagen COL1A1 and COL1A2 
gene were amplified using primers described previously 
[22] and listed in Table 1. The primers were designed 
and verified using PrimerSelect in DNAStar programme 
package version 5.0. The DNA was isolated from the 
proband’s cultured fibroblasts, using BloodMini DNA 
purification kit (A & A Biotechnologies, Gdansk, Po- 
land). The DNA was recovered from the kit column with 
1 mM EDTA buffered with 10 mM Tris-HCl pH 8.5 at 
final volume 150 μl and its concentration was determined 
spectrophotometrically at the wave length 260 nm and 
280 nm. Quality of the DNA was verified following its 
electrophoresis in 0.8% agarose gel. Until further analy- 
ses the DNA samples were stored at −20˚C. Concen- 
tra-tions of primers were calculated based on the sample 
absorbance at the wave length 260 nm and adjusted to 
the primer compositions. PCRs were performed accord- 
ing to the conditions described elsewhere [22]. Briefly, 
the reaction mixture included 300 ng double stranded 
patient genomic DNA, 1 µl 10 mM dNTPs (PCR nucleo- 
tide Mix, Roche, Germany), 1 µl (5 pmol) of each primer, 
2.5 µl 10x Taq polymerase buffer, 1U Taq polymerase  
and nuclease free water (all from FastStart Taq DNA 
Polymerase, Roche, Germany) to the total volume of 25 
µl. The mixture was denatured for 5 minutes at 95˚C, and 
incubated for 34 cycles of: 30 seconds at 95˚C, 30 sec- 
onds at 60˚C or 65˚C, depending of the Tm of the spe- 
cific pair of primers (Table 1), 30 seconds to 2 minutes 
at 72˚C depending on the length of the amplified DNA 
fragment. When the last cycle was completed the sam- 
ples were incubated for 7 minutes at 72˚C then cooled 
down and left at 4˚C. The PCR products (3 μl) were 
separated on 1% agarose gel (Agarose, LE, Analytical 
Grade, Promega, USA) in TAE buffer.  
2.4. PCR Conditions for DNA Sequencing 
The PCR for sequencing was conducted according to 
recommendations provided by the DNA Analyser 3130 × 
l ABI Prism, manufacturer (Applied Biosystems, USA). 
Briefly 10 to 20 ng of the PCR product was purified us- 
ing Shrimp Alkaline Phospatase (Fermentas, USA) and 
Exonuclease I, E. coli (Fermentas, USA). Clean product 
was then combined in semi-skirted 96-well PCR plate 
with 5 pM of primer, 8 μl of the ready to use mixture- 
provided by the manufacturer BigDye Terminator v3.1  
 
Table 1. Sequences of primers used for fragment amplification and for sequencing of the COL1A1 human gene. 
Fragment Exon No. and position 
Primers for fragment amplification  
(Amplified fragment length in bp) 
Primers for sequencing 
1 
420 - 522 
2 
1986 -2180 
3 
2322 - 2356 
4 
2468 - 2494 
1 
5 
2585 - 2686 
M1f 305-F  
GACGGGAGTTTCTCCTCGGGGTC 
N3R 2927-R 
GCGCAAAAGAGCCTGATGTTA 
[2622] 
M1f 
M2fk  
GGGAGGGGCGGGAAGTGAAAAAT 
N3R  
GCGCAAAAGAGCCTGATGTTA 
6 
3409 - 3480 
7 
3708 - 3752 
2 
8 
3911 - 3964 
N5F 2831-F  
GTTTGTGACATGTGCTTTATTAGT 
2RA1 4049-R  
GCTGGGATTGAAGGGAAGAGGTAA 
[1218] 
N6F AGTGCCGTCTTCTGCCTTTCA 
2RA1 
9 
4128 - 4181 
10 
4680 - 4733 
11 
4850 - 4903 
12 
5234 - 5287 
13 
5376 - 5420 
3 
14 
5537 - 5590 
N7F 3983-F  
GATTCATACTCCTTCTACAAAC 
3RA1 5647-R  
CTGGCCAGTCCCTAGAGTTCCT 
[1664] 
N7F 
N7R  
GGCACCATCCAAACCACTGAAA 
3RA1 
4FA1  
GAGCCTGGCAGCCCTGGTGAAAAT 
15 
5705 - 5749 
16 
5928 - 5981 4 
17 
6239 - 6337 
4FA1 5379-F  
GAGCCTGGCAGCCCTGGTGAAAAT 
5RA1 6436-R  
ACCAGGCTGTCCATCAGCAC 
[1057] 
4FA1 
5RA1 
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Continued 
18 
6426 - 6470 
19 
6574 - 6672 
20 
6804 - 6857 
5 
21 
7076 - 7183 
5FA1 6134-F  
CTGATCATTGCTCTCCTGTCCCTGT 
4RA1 7332-R  
CCCGGCCGCAAGGAGAGGTTAC 
[1198] 
5FA1 
W9FA1  
ACACCCTCAGCCCCTCGTCTC 
4RA1 
22 
7278 - 7331 
23 
7457 - 7554 
24 
7721 - 7774 
25 
7863 - 7961 
26 
8858 - 8911 
6 
27 
9055 - 9108 
6FA1 7166-F  
GGACCCCCTGGCGAGCGTGTAA 
6RA1 9166-R  
GGGGAGGCCGAGGAGACGAG 
[2000] 
6FA1 
8FA1  
AGGCCCTGGCTTCTCACTTCA 
28 
9212 - 9265 
29 
9377 - 9430 
30 
9882 - 9926 
31 
10020 - 10118 
32 
10416 - 10523 
7 
33/34 
10982 - 11089 
W9FA1 9153-F  
ACACCCTCAGCCCCTCGTCTC 
W9RA2 11221-R  
AGCCTCCCCTCCTTCTGGT 
[2068] 
W9FA1 
M30F  
GGGTTCCTCTCTAATCACGGCCAGACC 
W8FA1  
GCGGGGCTTAGGGCTGTGACC 
W9RA2 
35 
11310 - 11363 
36 
11527 - 11580 
37 
11799 - 11906 
38 
11995 - 12048 
39 
12175 - 12228 
40 
12369 - 12530 
41 
12632 - 12739 
42 
12897 - 13004 
8 
43 
13112 - 13165 
9FA1 10501-F  
GCTCCCATCTCTGCCTGCTTTGA 
W10RA3 13247-R  
TGGCGGGGAGAGCAGGGGAATA 
[2746] 
W9RA3  
ACGCCTTTGTCCTCATTC 
W9RA4 
CCCACCCAGCACCCCCAACCTA 
W10FA2  
TGTTCTCCCTCTGACTGTTCCTAT 
W10RA3 
44 
13270 - 13377 
45 
13758 - 13811 
46 
13924 - 14031 
47 
14370 - 14423 
9 
48 
14784 - 14891 
W10FA3 12800-F  
GCGGAGCCAAGGAGAACAGAT 
W11RA3 15311-R  
GCATCATCAGCCCGGTAGTAGC 
[2511] 
W10FA3 
M46r  
GGGGAAAGAATGACTATCCAG 
W11FA2  
CCCCTGGCCCTCCTGTAAGTATGC 
W11RA3 
49 
14983 - 15265 
50 
15398 - 15588 
51 
15877 - 16119 
10 
52 
16249 - 16395 
N9F 14922-F  
GCCCTCCAGCCCCCATAGCACT 
N10R 16599-R  
GGTTTTTGGTCATTGTTCGGTTGGT 
[1677] 
P48  
CATGTCCCTTCTGAGCACTGGGCTA 
N10F  
AGGTCCCTGCTAGTGGTTCA 
M51F  
GGACCCTGGACAGGAGGCCAGCAGG 
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Cycle Sequencing Kit (Applied Biosystems, USA) con- 
taining polymerase, dideoxy-NTP in the buffer and the 
final volume was obtained by adjusting it with water up 
to 20 μl. The mixture was incubated in the thermocycler 
by Eppendorf for 35 cycles with the following steps in 
the single cycle: denaturation for 30 seconds at 96˚C, 
annealing 15 seconds at 50˚C, elongation for 3 minutes 
at 60˚C. After completing the last cycle the sample was 
cooled down to 4˚C. The sequencing PCR product were 
purified by BigDye XTerminator Purification Kit (Ap- 
plied Biosystems, USA) according to manufacturers 
manual and put in the instrument for the DNA sequence- 
ing. The sequences were compared with reference se- 
quence (NG_007400.1 COL1A1 and NG_007405 COL1A2) 
using MegAlign in DNAStar programme package ver- 
sion 5.0. The differences were verified for final confir- 
mation by analysis of the raw chromatogram sequencing 
data using Chromas Lite version 2.01 freeware. 
2.5. Procollagen Type I Production and  
Purification  
Procollagen type I was produced using skin fibroblasts 
prior and following the bone marrow mesenchymal stem 
cells transplantation. The skin biopsies of the size of 5 
mm2 were obtained using surgical blade. The sample was 
minced into small pieces and placed on a 100 mm in di- 
ameter Petri dish containing 10 ml of Dulbeco’s Modi- 
fied Eagle’s Medium supplemented with 4.5 g/L glucose, 
(high glucose DMEM) 10% foetal calf serum (FCS), 10,000 
units penicillin, 10 mg units streptomycin, 25 μg/ml am- 
photericin B (all reagents from PAA The Cell Culture 
Company, Pasching, Austria). The medium was changed 
every other day. On day 7 of the culture the pieces of 
skin were removed and the fibroblasts were cultured un- 
til confluence. At 100% density the cells were transferred 
into T150 culture flask and maintained in the same me- 
dium until reaching 100% confluence when half of the 
culture was frozen, whereas, the other half was further 
cultured until 6 flasks of about 70% confluent were ob- 
tained. The procedure was followed for each sample. The 
fibroblast cultures were rinsed twice with sterile phos- 
phate buffered saline (PBS) and filled with 15 ml of se- 
rum-free high glucose DMEM supplemented with ascor- 
bic acid 50 μg/ml and all the other supplements as de- 
scribed above. The medium was collected every day and 
replaced with the fresh one for three consecutive days. 
Then for 24 hours the culture was fed on high glucose 
DMEM with serum. The procedure of washing with PBS, 
harvesting the serum-free medium and feeding with total 
complete medium were repeated 4 times.  
Harvested medium was processed as previously de- 
scribed [23] with subsequent modifications described 
elsewhere [22,24]. The volume of sample containing 
procollagen I was reduced to the appropriate collagen 
concentration using Amicon cell under nitrogen pressure 
fitted with the membrane with the size cut off 100,000 
kDa, following double dialysis against 200 volumes of so 
called storage buffer containing 0.4 M NaCl, 0.1 M 
Trizma Base (pH 7.4) supplemented with 0.025 M 
EDTA and 0.04% NaN3.  
2.6. Preparation of Collagen Type I and Its  
Triple Helix Thermal Stability Assay  
The procollagen type I sample was treated with acetic 
acid to adjust pH to about 2.0. Pepsin was added to the 
acidified procollagen to a final concentration 200 μg/ml. 
The digestion with pepsin was carried at 10˚C for 18 
hours, than terminated by raising pH to 7.5. The concen- 
tration of collagen was determined using kit by Biocolor 
(Ireland). Stability of collagen triple helix was assessed 
using J-815 Spectropolarimeter (Jasco) at 220 nm, using 
a 0.5 mm path-length thermostated cell. The temperature 
was controlled by a circulating water-bath. The tempera- 
ture changes were controlled by a programmable con- 
troller (Jasco Peltier) which increasing temperature of 
collagen from 20˚C to 45˚C.  
Stability of collagen triple helix was calculated by us- 
ing Spectra Manager Program and Statistica 8. 
2.7. Bone Mineralization Assay 
Osteoblasts were detected by staining for the presence of 
hydroxyapatite in the culture using Alizarin Red-S 
(AR-S), following fixation in cold 70% ethanol at −20˚C. 
At indicated osteoblast’s differentiation time points, the 
medium was removed and the culture was washed with 
PBS followed by fixation in ice-cold 70% ethanol for at 
least 1 hour. Subsequently, the ethanol was removed, and 
fixed cells were rinsed with de-ionized water, then 
stained with 40 mM AR-S (pH 4.2) for 10 minutes at 
room temperature. After staining the cells were further 
processed by rinsing them five times with water followed 
by 15 minutes wash with PBS to remove nonspecifically 
bound AR-S. The specimens were photographed and 
immediately processed for minerals content. Therefore, 
bound AR-S was solubilized with10% cetylpyridinium 
chloride (CPC) in 10 mM sodium phosphate, pH 7.0, for 
15 minutes at 25˚C. Recovered AR-S was diluted 10-fold 
in 10% CPC solution, and the AR-S concentration was 
determined by measuring the absorbance at 562 nm wave 
length using an AR-S standard curve in the same solution 
[25,26]. The values were normalized per 1000 cells. The 
measurements were conducted in quadruplicates. 
2.8. Isolation of BM-MSCs 
Bone marrow derived mesenchymal stem cells (BM- 
MSCs) were obtained from healthy patient’s father after 
written consent according to the protocol approved by 
the Jagiellonian University Bioethical Committee 
(KBET/108/B/2007). Bone marrow (150 ml) was har- 
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vested under anesthesia from the posterior superior iliac 
crest by multiple aspirations. Aspirates were collected in 
a Bone Marrow Collection Kit with Pre-Filter and Inline 
Filters (Baxter, USA) and further processed. Light- 
density mononuclear cells (MNC) were separated on a 
Lymphocyte Separation Medium (PAA Laboratories 
GmbH, Goetzis, Austria) by density gradient cen- 
trifugation at 400 g for 30 minutes at room temperature. 
MNC were washed twice with Dulbecco’s phosphate 
buffered saline (PAA Laboratories) and suspended in 
culture medium. 
Culture of BM-MSCs 
Bone marrow mononuclear cells were plated into vented 
75 cm2 tissue culture flask (Sarstedt, Newton USA) with 
Dulbecco’s-Modified Eagles Medium (DMEM, Sigma- 
Aldrich Germany D5523) supplemented with 10% FBS 
(Stem Cell Technologies, Vancouver Canada 06472) and 
antibiotics (PAA Laboratories GmbH, Goetzis, Austria). 
Flasks were incubated at 37˚C in a humidified atmos- 
phere containing 5% CO2 and after 7 days medium was 
replaced with a fresh one. Than the cells were cultured 
with a medium change every week until confluence. On 
reaching confluence, the adherent cells were detached 
using 0.25% trypsin and re-seeded at 75 cm2 flask (first 
passage). At the end of second passage when the cells 
reached confluence, they were trypsinized and checked 
for heamatopoietic contamination [27].  
2.9. Flow Cytometry 
MSC phenotype was analyzed with mouse antibodies 
specific for human CD45 and CD3 antigens (Becton 
Dickinson). Briefly, to 1 × 105 cells suspended in 100 µl 
of staining buffer (PBS, 2% FBS) 20 µl of mouse 
antibodies was added. Next, the cells were incubated in 
the dark for 30 minutes at 4˚C. Stained cells were 
washed, collected and analyzed using FACS Calibur 
cytometer (Becton Dickinson, USA).  
2.10. Infusion of the MSC 
Cells were harvested after the second passage in two 
parts in two weeks time. Each time cells were suspended  
in 10 ml of normal saline and passed through a filter 
before infusion. The patient received two 15- to 
30-minutes intravenous infusions of MSCs 16 days apart. 
Target doses for the first and second infusions were 4.0 × 
106 cells/kg of body weight and 3.9 × 106 cells/kg, 
respectively. Directly before infusion the patient received 
hydrocortisone. The girl was evaluated for toxicity 
(physical examination, complete blood count, clinical 
chemistry panel-BUN, glucose, AST, ALT, ALKP, urine 
analysis, before, and 24 hours after, each infusion. She 
was monitored at the bedside during, and for 6 to 8 hours 
after, each infusion. Nine days after first infusion she 
received a course of the Vancomycine because of 
positive blood culture for Staph. Epidermidis. During the 
bacteremia period she was stable and in a good general 
status. The period of two weeks after the second infusion 
was uneventful. Then she developed G(−) sepsis with 
Enterobacter cloacae treated with Meropenem and III 
generation cephalosporin antibiotics. She recovered from 
sepsis after two weeks and her general status was quite 
good. 
Three months after MSC transplantation a bone 
marrow biopsy (for assessment the chimerism and 
cellular differentiation) and a skin biopsy (for evaluation 
the stability of collagen triple helix) were performed. 
Another blood sample was taken to molecular analysis of 
COL1A1 and COL1A2 genes. 
The patient was finally discharged from hospital at the 
age of four months. She has had regular appointments in 
a genetic out-patient clinic (at the beginning every month, 
now every two months). Each visit consists of: history 
taking, physical examination, anthropometric measure- 
ments and collecting blood sample to assess the level of 
serum bone turn over markers. 
3. RESULTS 
3.1. Cells Expansion 
Expansion of the cells resulted in harvesting 4 × 106 cells 
and 3.9 × 106 cells. Two infusions with collectively of 
7.9 × 106 MSC were performed. Expanded cells con- 
tained 7.3% of hematopoietic contamination, but did not 
contain lymphocyte contamination (Figure 1). 
 
 
Figure 1. Majka M. et al. Cell therapy of a patient with type III osteogenesis imperfecta... 
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3.2. Patient Follow-Up 
Patients follow up was performed monthly. Physical 
examination of the patient revealed short stature, severe 
lower limb deformities, relative macrocephaly, triangular 
face, blue sclera and dentinogenesis imperfecta. The 
antropometric measurements show extremely retarded 
growth (Table 2). The child’s psychomotoric develop- 
ment was not synchronic—motoric development is re- 
tarded, while the speech development and cognitive 
functions are adequate to the chronological age. The pa- 
tient is under the constant care of physiotherapist, ortho- 
pedic surgeon, psychologist and dentist. An objective 
audiology (ABR, AOE) examination was not possible to 
perform so far. Nevertheless, there is no signs of hearing 
loss in our patient.  
The patient has had six bone fractures since her birth 
of which five were identified during the performance of 
diagnostic bone marrow biopsy after the MSC infusion. 
During the afterwards follow up over the period of two 
years two new fractures were diagnosed. The results of 
serum bone markers levels did not revealed any 
clinically significant tendencies.  
Stability of collagen triple helix assessed in skin fibro- 
blasts taken prior to bone marrow MSC transplantation 
showed temperature of 2˚C lower than normal. Stability 
of collagen triple helix assessed in skin fibroblasts taken 
after the MSC transplantation returned to the normal 
temperature range (Figure 2).  
The molecular analysis of the gene COL1A1 per- 
formed prior to and following the MSC transplantation 
did not reveal any mutation. A missense mutation 
 
 
Figure 2. Majka M. et al. Cell therapy of a patient with type III 
osteogenesis imperfecta... 
G23569A changing glycine at position 517 to aspartate 
(p.Gly517Asp) was detected in the exon 26 of COL1A2 
gene before and after the MSC transplantation. This 
particular mutation was previously identified in one 
patient with type III osteogenesis imperfecta reported to 
Osteogenesis Imperfecta Variant Database.  
3.3. Bone Mineralization 
Data on differentiation of bone marrow cells to 
osteoblasts measured indirectly as mineral deposition are 
inconclusive. Although the bone marrow MSC collected 
following transplantation could be successfully expanded 
during process of differentiation their number decreased 
with time. The experiments were repeated three times in 
quadruplicates and none of them was successful. The 
control sample in this experiment was established culture 
of stem cells purified from human normal placenta. The 
cells grew accordingly during differentiation and 
revealed increasing mineral deposition expressed as 
amount of calcium ion bound to AS-R (Figure 3). 
3.4. Chimerism 
Genetic profile of transplanted patients were studied 
using AmpFlSTR SGM which recognized 11 STR loci. 
Only DNA of patient was detected indicating low 
engraftment of donor MSC.  
4. DISCUSSION 
Type III OI is known as progressive disease leading to 
serious skeletal deformations and severe handicap. Its 
presentation at birth is phenotypically similar to the 
milder end of the spectrum of type II disease. Although 
this form of the disorder is usually not life threatening, 
some children with type III OI die in infancy because of 
respiratory distress, whereas others die in childhood due 
to pneumonia, pulmonale or trauma. For those, who sur-
vive, there is progressive deformity of long bones and 
spine, which in combination with compression of verte 
brae, contributes to marked short stature. Most of the 
patients with type III OI are severely physically handi- 
capped and have traditionally required multiple ortho- 
pedic procedures and wheelchairs for mobility.  
In fact, there is no effective treatment for the patients 
with OI so far [27-30]. That is why, it seems to be of 
crucial importance to continue research studies inves- 
tigating the role of new methods of therapy in patients 
with this disease. A development of new treatment could 
improve the prognosis and reduce unnecessary exposure 
to potentially painful therapies. 
 We conducted a study examining the role of cell 
therapy in patients with type II and III OI. Till now, we 
enrolled one trial subject. MSC were administered   
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Table 2. Sequences of the primers used for fragment amplification and for sequencing of the COL1A2 human gene. 
Fragment Exon No. and position 
Primers for fragment amplification (Amplified 
fragment length in bp) 
Primers for sequencing 
1 
1 
5742 - 5541 
2FA2 5364-F  
AGTTGGAGGTACTGGCCACGACTG 
2RA2 7289-R  
TTAGGTGGCCAAGAAGTGCGTTAT  
[1925] 
2FA2  
2 
8188 - 8198 
3 
8822 - 8836 
4 
9489 - 9524 2 
5 
10636 - 10728 
3FA2 6944-F  
TTGAGAGTGGGAGGAAAGAGTCG 
N2RA2 11159-R  
GTCAAGGAGAATAAAAAGCGTAGG  
[4216] 
4FA2 
TGCTGATCCCTGCCATACTTTTGAC 
JK3F  
GTGAAGGTATATTTGTATACTACAC 
JK3R 
TGTTATCTTAAACATCAAAGCTAC 
JK4F 
CATTGTAGTTACATCAGTCTTACC 
7FA2 
N2RA2 
3 
6 
12007 - 12060 
7FA2 10526-F  
TCCACCCTACTTGCACATAGAAAGG 
7RA2 13393-R  
TTAGGGAATTAGAAGTCGTCAA 
 [2867] 
JK6F 
TCGGCCAAGTTTTTGACGTACAGCT 
JK6R 
TGGCGTGGTAAAATGTGACATAAAA 
7 
16996 - 15040 
8 
15133 - 15186 
9 
15279 - 15332 
10 
15639 - 15692 
11 
16113 - 16166 
12 
16690 - 16743 
4 
13 
18287 - 18331 
9FA2 14753-F  
TAAGGAACCTATCTGCCCCGTCTA 
10RA2 18544-R  
TTCCAACCTGTACAAGAATACACT [3791] 
9FA2 
JK10/11F 
ACCAAGATTCCCCCATTTGTGCTGA 
9RA2 
GAAGTCCAGTGTTCCAGGTCCCAGC 
JK12R 
TGGAGGTCATGGGGAATTTCAATCA 
11FA2 
14 
18623 - 18676 
15 
18776 - 18820 
16 
19210 - 19263 
17 
19762 - 19860 
18 
20004 - 20048 
5 
19 
20163 - 20261 
11FA2 18118-F  
GAACCTGGATATGTGGTACTATCTG 
N5RA2 21572-R  
CAGGGCCACTTGCACCACGACTA [3455] 
JK14F 
CTTGTACAGGTTGGAAACTGAAC 
JK14R 
CCACGGGCACCCTAAGAAGA 
JK15F 
CCGTGGGCTTCCTGGTGAGAG 
JK16F 
CACCCTGGATACCATGAATGTC 
11RA2 
TTCTTCTTCTTCCCCATACTCCAC 
12FA2 
JK18FB 
CGTTGGACCTCCTGTAAGTAG 
JK19F 
TAATGTGTGCTGCCTCTACAGC 
 
20 
20682 - 20735 
21 
20860 - 20967 
22 
21329 - 21382 6 
23 
21496 - 21594 
 
12FA2 19891-F  
AGTAAAAGAAAACAAAGGTGGAGT 
12RA2 22245-R  
TGTATATGGGCAAAATGTATCACG 
[2354] 
JK20F 
CTTGAGCTTCTCTTTACCTTGAC 
JK21F 
CGTAAGTAGCTCTATCATCAC 
JK22/23F 
GGGTTGGGTGAAGTGTTTTGGCTTG 
JK23RB 
GCAACTGTCAGCAAGACTAC 
7 
24 
22508 - 22561 
25 
23024 - 23122 
 
13FA2 22124-F  
CCACAAACAAGTAATAGGGACACC 
13RA2 23663-R  
13FA2 
JK24F 
AAAAAGTCGGGGGAAAAGGTGCCTT 
JK25/26F 
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26 
23523 - 23576 
CAAAATGATATCAGATGGTGTAAA [1539] 
TTTCATCCGTGGCAGCATCATAAGC 
JK25R 
CTGAGACTGGACTGATTCGCAG 
JK26R 
TATCAGATGGTGTAAAAAAAAAAGTGTGGTTCT-
TAGATG 
JK26FB 
TGGAGCTGCATGGTGATGGATC 
27 
24130 - 24183 
8 
28 
24334 - 24387 
14FA2 23556-F  
CTGGTCTTGCTGGTGCTCGGGTAG 
14RA2 25707-R  
TGGACCAGCAGGACCAGGGAGACC [2151]
14FA2 
JK27/29F 
GCTTTCGTGGGAACCCACAATGAGT 
JK27RB 
TAGCAACGTATGTCACCACTG 
JK28RB 
TGCTTCAGTCCTGAAATCATGT 
29 
24662 - 24705 
30 
25666 - 25110 9 
31 
26845 - 26943 
15FA2 24540-F  
GCTTAATAACATACAATCGTGCTC 
15RA2 27582-R  
ACATCCTTCCATACACTAAAATAG 
[3042] 
15FA2 
JK30F 
TGCACTCATGTAGATACTGCCAGGT 
JK31F 
AAACCAGGGCTCGGAAGCTACACAA 
32 
28164 - 28271 
33 
28939 - 28992 10 
34 
29938 - 29991 
16FA2 27185-F  
GGTTGTCACTCTTTTCTCCTCACG 
16RA2 30032-R  
TTTTAGATATTGCTGTTGGCTTAG 
[2847] 
JK32F 
TCTCCCTCCTTTCAATAGCCCAGCC 
JK33F 
GAATGGTAAGGAATCGAGACATTGC 
JK34F 
GGAGTACCCTCCTTCTGAGAGTGGC 
35 
30673 - 30726 
36 
30831 - 30884 
37 
30981 - 31088 
11 
38 
31449 - 31502 
JK35F 30535-F  
ACTCTGTGAGATGTGCGTCAG 
JK40RB 33651-R  
CATCAACAAATAGATGCCACTTG 
 [3116] 
JK35F 
JK38F 
TGCGGGAATGATCCACTTGAAGAA 
JK36/37F 
GAAGCCCTGTAAGTAAGAACCTG 
JK37R 
CTTCCGTTATTTTCCATCTTCTATC 
JK38R 
TCGGAATTGCTCTGAATAGAATGAA 
39 
32339 - 32392 
40 
33397 - 33558 
12 
41 
34776 - 34883 
 
17FA2 31958-F  
GGTCATTTGTTATTCTTTTGTCCA 
N13RA2 35305-R  
GATGGTTTCTAGTTGTTGTCACG 
[3348] 
17FA2 
JK39RB 
GAAAAGCTGACTTCAGACCAGGAG 
JK39FB 
GAAATTCCCATCTTACCCAAATTCTTG 
JK40RB 
JK40FB 
CATAAAGGAAGACAGGAGTTGC 
17RA2 
CTCATTTATTGTCTTCCCGATTTG 
JK41F 
CTCACAATCTTCAAGCCAACCTGTG 
JK41R 
TCTGTCACATTTGAAGTGGCAGCTT 
N13RA2 
42 
35557 - 35664 
43 
36050 - 36103 
44 
36190 - 36297 
13 
45 
36438 - 36491 
18FA2 35302-F  
TTTGGGATACTGAATGACACG 
18RA2 36985-R  
CTACAGTTTACTTACAGCGATACC 
[1683] 
18FA2 
JK43F 
AGGGTTCGTTACTGAGCACTG 
JK44F 
ATGGTCAACCCGGACACAAG 
JK45FB 
GTGGGCTTCACTTCTGACTTC 
46 
36863 - 36970 
47 
37448 - 37501 14 
48 
37628 - 37735 
N15FA2 25691-F  
GTGAAGCTGGTCGTGATGTGAGTC 
19RA2 38998-R  
TATTTAGCAGAAGGAGAGGTGTTT 
[3308] 
JK46F 
GCAGATTACCAGCAGAGGTGAGAGC 
JK47R 
GACACCAGGTACATGTGAGCTG 
JK47/48R 
TGGGGCTAACTTTAATGGGTTGTC 
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49  
38067 - 38325 
 
JK49FB 
GAACATGCTTCCGTGTGAAGCTC 
JK48F 
CAAGAGAAGACAGTTCATCTCTG 
50 
38733 - 38917 
51 
39628 - 39870 15 
52 
40687 - 40833 
20FA2 38643-F  
CTCTTCCTCTTAAATATGGGGTAG 
N16RA2 41458-R  
AAAAATACACCACACGATACAAC 
[2815] 
JK50FB 
TGTTACTTATGAGAGTCAGTATCTTTC 
JK51F 
CCCTTTTCCTAAGCTTGGATCTGAG 
JK51R 
TTAACCCCCCTTTAGACCCCCCTTG 
JK52FC 
GGACAGACATCTTCAGAATGAC 
 
 
Figure 3. Majka M. et al. Cell therapy of a patient with type III osteogenesis imperfecta... 
 
Intravenously. The most significant observation in the 
present study is the association between the MSC 
transplantation and the improvement of stability of col- 
lagen triple helix, and a decrease in a number of fractures 
observed in our patient. Stability of collagen triple helix 
after the MSC transplantation was normal, and there was 
only two bone fracture noted two years after the bone 
marrow stem cells transplantation. To validate this 
finding we measured serum bone markers levels, but 
they did not revealed any observable tendency. Never- 
theless, during the first 2 years of life, the child had 
significant growth deficiency. Anyway, we can speculate 
that the cell therapy in patient with type III osteogenesis 
imperfecta looks promising. However, further evaluation 
is necessary. 
two years after the transplantation. No cases of rejection 
reaction when the father’s MSCs are injected into the 
girl’s body were previously reported from other trials 
with the use of purified cells [17,18]. Therefore, in this 
study the graft versus host disease symptoms also were 
not observed. In conclusion, although, the assay of in 
vitro osteogenesis by minerals deposition was inconclu- 
sive, altogether the results indicate that they might be 
considered as an objective indicators of partial success of 
the cell therapy. It is very important for further clinical 
trials of cell therapy in the OI because no reports are 
available on remission of this disease, especially of its 
most severe type III. 
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